Bridging Connections and Insights from Investment Conferences

Bridging Connections and Insights from Investment Conferences

By Punit Dhillon, CEO and President of OncoSec Medical Incorporated

After the conclusion of several conferences this past month, I’ve had time to reflect on key takeaways and principal trends emerging in the healthcare sector. Despite less than stellar market conditions, speakers at conferences (such as J.P. Morgan 2016 and Bio CEO) and ancillary events remained optimistic and highlighted important insights into the future of healthcare. After a busy schedule with non-stop meetings and presentations, I returned home confident in OncoSec’s place in the burgeoning cancer immunotherapy landscape.

OncoSec Rings Nasdaq Opening Bell

We were thrilled to participate in the Nasdaq Opening Bell Ceremony to celebrate our recent listing to The Nasdaq Capital Market. This marks an exciting and significant milestone for our company as we continue to build on our success and advance our technologies to one day benefit patients everywhere.

Upward and Onwards: OncoSec Moves to The NASDAQ Capital Market

On May 27th, we proudly announced that our common stock has been listed on The NASDAQ Capital Market. We’re very excited to be following an upward trajectory and expect this milestone will bring several benefits to the company, ranging from appealing to a broader set of investors to increasing the visibility of OncoSec’s capabilities.

OncoSec Medical Announces Reverse Stock Split in Preparation for Proposed Uplisting to NASDAQ Capital Market

On behalf of OncoSec, I want to thank our shareholders for their ongoing support of our mission to develop novel intratumoral immunotherapies to treat cancer. To date, the company has never been stronger in terms of our ImmunoPulse™ technology, advanced clinical pipeline, and collaborations with academic and industry institutions.

Rodman & Renshaw Presentation Overview

This week, our CEO, Punit Dhillon, presented at the 15th Annual Rodman & Renshaw Global Investment Conference. The annual event hosted over 150 established and emerging biotech and pharmaceutical companies. During the presentation, Mr. Dhillon reviewed previous data points and provided an update on upcoming milestones. Here is an overview of the presentation:

In OncoSec’s active pursuit of knowledge in the cancer and biotech realms, we come across a vast number of articles that we believe exhibit strong signs of importance, within our industry. While we regularly share some of these with our online community, we would like to start highlighting certain news articles, study data, and other materials. Here are three articles we are currently reading:

Aging Population of Canada and Biotech

Many conditions and diseases are more likely to occur at an older age. Lifetime risk factors, the deterioration of the body and immune system, and a lack of diet and fitness regiments all add up to a greatly increased risk of diseases such as cancer. While society is making leaps and bounds in medical advancements, new treatment methods and life prolonging procedures invented in the biotech industry take an enormous amount of funding. In Canada, the very rapidly aging population is especially in need of biotech advancements – now more than ever.

Upcoming Conferences: March-April 2013

North America is home to some incredible conferences and conventions surrounding cancer research, therapy development and biotech investments. With the strength of the American biotech and life sciences industries, several of these lineage conferences have been around for decades. Many CEOs, scientists and clinical experts speak at the various events and chair panels to create discussions on various topics that are currently of large importance in medicine. Each quarter, we attend or keep our eye on at least a few of these events. For March and April, these are 4 of the upcoming conferences that we are interested in:


Real Time Web Analytics